JP2836206B2 - Oil composition for inflammatory bowel disease - Google Patents
Oil composition for inflammatory bowel diseaseInfo
- Publication number
- JP2836206B2 JP2836206B2 JP17488590A JP17488590A JP2836206B2 JP 2836206 B2 JP2836206 B2 JP 2836206B2 JP 17488590 A JP17488590 A JP 17488590A JP 17488590 A JP17488590 A JP 17488590A JP 2836206 B2 JP2836206 B2 JP 2836206B2
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory bowel
- bowel disease
- oil
- linolenic acid
- oil composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、炎症性腸疾患の治療効果を有する油脂組成
物に関する。Description: TECHNICAL FIELD The present invention relates to an oil / fat composition having a therapeutic effect on inflammatory bowel disease.
炎症性腸疾患とは、今日では原因不明の潰瘍性大腸炎
とクローン病の２つの疾患をさす。Inflammatory bowel disease refers to two diseases, ulcerative colitis, of unknown origin today and Crohn's disease.
潰瘍性大腸炎は、大腸とくに直腸の主として粘膜をお
かし、しばしばびらんや潰瘍を形成する疾患であり、ク
ローン病は、消化管のどの部分にも起こり得る、線維化
や潰瘍を伴う肉芽腫性炎症性病変であり、経過が長く難
治性である。Ulcerative colitis is a disease that affects the mucous membranes of the colon, especially the rectum, and often forms erosions and ulcers. It is a recurrent lesion with a long course of refractory disease.
炎症性腸疾患の治療は、外科治療と内科治療により行
なわれるが、手術後の再発が多いことから、内科治療が
主体となっている。内科治療は、薬物療法と栄養療法に
大別される。薬物療法では、ステロイド剤、SASP（sala
zosulfapyridine）、免疫抑制剤などが用いられるが、
いずれも副作用が強い。栄養療法は、静脈栄養法または
経腸栄養法により行なわれ、腸管を刺激しないことが重
要である。静脈栄養法では、糖類、アミノ酸、電解質、
ビタミン類を含む高カロリー輸液を経静脈的に行なう
が、副作用が起こるので注意が必要とされている。ま
た、経腸栄養法は、アミノ酸を窒素源とし、脂肪をほと
んど含まない成分栄養剤が中心であるが、長期投与の場
合には脂肪乳剤を静脈投与しなければならない。Treatment of inflammatory bowel disease is performed by surgical treatment and medical treatment. However, since there are many recurrences after surgery, medical treatment is mainly performed. Medical treatment is roughly divided into drug therapy and nutrition therapy. In pharmacotherapy, steroids, SASP (sala
zosulfapyridine), immunosuppressants, etc.
All have strong side effects. Nutrition therapy is provided by parenteral or enteral nutrition and it is important that the intestinal tract not be stimulated. In parenteral nutrition, sugars, amino acids, electrolytes,
High-calorie infusions containing vitamins are given intravenously, but caution is needed because side effects occur. In the enteral nutrition method, a nutrient containing amino acids as a nitrogen source and containing almost no fat is mainly used, but in the case of long-term administration, a fat emulsion must be administered intravenously.
一方、α−リノレン酸は、いろいろな機能が見出され
ており、例えば、アレルギー症、血栓症、高血圧症の予
防効果を有するこ（特開昭63−36744号公報参照）、老
齢時の脳卒中発作又は識別能低下を抑制させること（特
開昭64−3117号公報参照）、腫瘍細胞の転移を抑制させ
ること（特開昭63−154626号公報参照）、などがある。On the other hand, α-linolenic acid has been found to have various functions. The method includes suppressing seizures or loss of discrimination ability (see JP-A-64-3117) and suppressing metastasis of tumor cells (see JP-A-63-154626).
本発明は、炎症性腸疾患の治療のうち、栄養療法にお
いて、その症状の治療効果を増強する組成物の開発を課
題とする。An object of the present invention is to develop a composition that enhances the therapeutic effect of a symptom in nutritional therapy among treatments for inflammatory bowel disease.
本発明者らは、α−リノレン酸を含有する油脂組成物
が炎症性腸疾患の治療効果を増強することを見い出し、
本発明を完成するに到った。The present inventors have found that an oil / fat composition containing α-linolenic acid enhances the therapeutic effect of inflammatory bowel disease,
The present invention has been completed.
本発明に係る油脂組成物は、α−リノレン酸と必須脂
肪酸であるリノール酸を含みリノール酸とα−リノレン
酸との重量比が1:3以上であることを特徴としている。
さらに、本発明においては、α−リノレン酸を少なくと
も40重量％以上含むことが好ましい。The oil / fat composition according to the present invention is characterized in that it contains α-linolenic acid and linoleic acid as an essential fatty acid, and the weight ratio of linoleic acid to α-linolenic acid is 1: 3 or more.
Furthermore, in the present invention, it is preferable that α-linolenic acid is contained at least 40% by weight or more.
これらの油脂組成物は、植物より得られるペリラ油
（シソ油）、アマニ油、エゴマ油などの油脂に含まれて
いる。例えば、ペリラ油の油脂組成物は、α−リノレン
酸を50〜60％、リノール酸を12〜17％含んでいる。ま
た、本発明においては、このようなペリラ油に限らず、
オリーブ油、サフラワー油、コーン油、月見草油などを
適宜組み合わせて用いることも可能である。These oil and fat compositions are contained in oils and fats such as perilla oil (perilla oil), linseed oil, and perilla oil obtained from plants. For example, the oil and fat composition of perilla oil contains 50-60% of α-linolenic acid and 12-17% of linoleic acid. Further, in the present invention, not limited to such perilla oil,
Olive oil, safflower oil, corn oil, evening primrose oil and the like can be used in appropriate combination.
本発明においては、α−リノレン酸として１日当り３
〜6gとなるように数回に分けて摂取するとよい。この摂
取量は、患者の症状、体重等により調整する。投与方法
としては、傾向投与が適しているが、非経口、経腸など
の投与でもよい。経口投与の場合は、従来の添加物、例
えば、シロップ、アラビアゴム、ソルビトールなどを含
むことができ、また、α−リノレン酸の酸化による変質
を防ぐため、抗酸化剤を添加することができる。In the present invention, the amount of α-linolenic acid is 3 per day.
~ 6g should be taken in several divided doses. This intake is adjusted according to the patient's condition, body weight, and the like. As the administration method, trend administration is suitable, but parenteral administration, enteral administration and the like may also be used. In the case of oral administration, conventional additives such as syrup, gum arabic, sorbitol and the like can be contained, and an antioxidant can be added in order to prevent deterioration due to oxidation of α-linolenic acid.
次に、本発明を実施例により詳しく説明する。 Next, the present invention will be described in more detail with reference to examples.
実施例1. クローン病の患者５名に、α−リノレン酸を多量に含
むペリラ油（α−リノレン酸56％；リノール酸14.5％）
を250mgのゼラチンカプセル化し、6g/日の量で２週間投
与した。Example 1. Perilla oil containing a large amount of α-linolenic acid (α-linolenic acid 56%; linoleic acid 14.5%) in 5 patients with Crohn's disease
Was encapsulated in gelatin at 250 mg and administered at a dose of 6 g / day for 2 weeks.
ペリラ油の投与前後において、炎症性腸疾患における
炎症の重要なメディエーター物質であるLTB4（ロイコト
リエン）を測定した。Before and after the administration of perilla oil, LTB 4 (leukotriene), an important mediator of inflammation in inflammatory bowel disease, was measured.
結果を表−１に示す。 The results are shown in Table 1.
以上の結果より、本物質に係る油脂組成物は、血中の
LTB4を、低下させ、炎症性腸疾患に対し、治療効果を有
することが明らかである。 From the above results, the oil and fat composition according to this substance is
The LTB 4, is lowered, to inflammatory bowel disease, it appears to have a therapeutic effect.
本発明により、炎症性腸疾患に対し、治療効果を有す
る油脂組成物が提供される。According to the present invention, an oil / fat composition having a therapeutic effect on inflammatory bowel disease is provided.
Claims (2)
を含み、リノール酸とα−リノレン酸の重量比が1:3以
上であることを特徴とする炎症性腸疾患用油脂組成物。1. An oil or fat composition for inflammatory bowel disease comprising at least α-linolenic acid and linoleic acid, wherein the weight ratio of linoleic acid to α-linolenic acid is 1: 3 or more.
％である請求項１記載の組成物。2. The composition according to claim 1, wherein the content of α-linolenic acid is at least 40% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17488590A JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17488590A JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0466528A JPH0466528A (en) | 1992-03-02 |
| JP2836206B2 true JP2836206B2 (en) | 1998-12-14 |
Family
ID=15986372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17488590A Expired - Lifetime JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2836206B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT754001E (en) * | 1994-04-01 | 2002-07-31 | Abbott Lab | NUTRITIONAL PRODUCT FOR THE TREATMENT OF ULCERS AND THEIR UTILIZATION |
| GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| JP5207341B2 (en) * | 2006-10-26 | 2013-06-12 | 独立行政法人産業技術総合研究所 | Inflammatory cytokine production inhibitor |
-
1990
- 1990-07-02 JP JP17488590A patent/JP2836206B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0466528A (en) | 1992-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1602372B1 (en) | Drug for improving prognosis for subarachnoid hemorrhage | |
| JPH06157303A (en) | Fatty acid medical treatment | |
| JP2010100655A (en) | Composition and method for treatment of gastro-intestinal tract of inflammatory condition | |
| US20070259037A1 (en) | Method and composition for treatment of inflammatory conditions | |
| EP1237545B1 (en) | Use of stearidonic acid in the manufacture of a medicament for the treatment or prevention of cancer | |
| JP2004531568A (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
| JP2010100655A6 (en) | Composition and method for the treatment of inflammatory gastrointestinal tract | |
| JP2008501686A (en) | Nutritional product | |
| JPH06199663A (en) | Method for therapy of schizophrenia | |
| HUE028065T2 (en) | Compositions for the treatment of neurologic disorders | |
| US20020002154A1 (en) | Method and composition for treatment of inflammatory conditions | |
| JP2836206B2 (en) | Oil composition for inflammatory bowel disease | |
| JP2003508487A (en) | Methods for treating cell proliferative disorders, including cancer | |
| CA2906491C (en) | Medicament for treatment of cancer, cardiovascular diseases and inflammation | |
| US20100239660A1 (en) | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions | |
| CN115916152A (en) | Parenteral nutritional formulation | |
| Russell et al. | Elemental diet therapy in the management of complicated Crohn's disease | |
| JP4394174B2 (en) | Inflammatory bowel disease treatment | |
| US5602180A (en) | Method of administering EDTA complexes | |
| Falconer et al. | Polyunsaturated Fatty Acids in the Treatment of Weight-Losing Patients with | |
| JPH06271464A (en) | Arachidonic acid-containing composition for prevention or improvement of alimentary disorder | |
| EP3429625B1 (en) | Method of treatment of obesity | |
| JP3816545B2 (en) | Composition for treatment of cutaneous pruritus and composition for treatment of hyperparathyroidism in an artificial dialysis patient | |
| WO2005046668A1 (en) | Preventive/therapeutic agent for speech disorder | |
| Giancaterini et al. | Effects of propyonil-l-carnitine topical irrigation in distal ulcerative colitis: a preliminary report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 12 Free format text: PAYMENT UNTIL: 20101009 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101009 Year of fee payment: 12 |